8-K current report · filed Oct 23, 2026

Arcus Biosciences, Inc. (RCUS) 8-K Current Report: October 23, 2026

Item 8.01RCUS overview

Short answer

Arcus Biosciences, Inc. (RCUS) filed an 8-K current report with the SEC on October 23, 2026 reporting Item 8.01 (Other Events). $269.7 million net proceeds strengthen Arcus’s cash position for development and corporate activities.

Arcus Biosciences, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • $269.7 million net proceeds strengthen Arcus’s cash position for development and corporate activities
  • 16,428,572 shares issued at $17.50 public offering price, creating material equity dilution
  • Underwriters exercised the full 2,142,857-share option, signaling completed demand for the offering
  • Company received $16.45 per share after underwriting discounts and commissions before offering expenses

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Arcus Biosciences, Inc. 8-K filings

Get the next RCUS 8-K as it lands

Follow RCUS for push alerts, or ask the research agent what this filing means.